<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Breath of the Willebrand - Benign Hematology Quest</title>
    <link href="https://fonts.googleapis.com/css2?family=Press+Start+2P&display=swap" rel="stylesheet">
    <style>
        :root {
            --hyrule-green: #1a472a;
            --hyrule-dark: #0d2818;
            --gold: #FFD700;
            --gold-dark: #B8860B;
            --triforce-gold: #F4C430;
            --nayru-blue: #4169E1;
            --din-red: #DC143C;
            --farore-green: #228B22;
            --heart-red: #FF0000;
            --heart-dark: #8B0000;
            --rupee-green: #00FF00;
            --rupee-blue: #0000FF;
            --rupee-red: #FF0000;
            --rupee-purple: #800080;
            --slate: #2F4F4F;
            --parchment: #F5DEB3;
        }

        * { margin: 0; padding: 0; box-sizing: border-box; }

        body {
            font-family: 'Press Start 2P', cursive;
            background: linear-gradient(180deg, var(--hyrule-dark) 0%, var(--hyrule-green) 50%, var(--hyrule-dark) 100%);
            min-height: 100vh;
            color: #fff;
            overflow-x: hidden;
        }

        .game-container {
            max-width: 900px;
            margin: 0 auto;
            padding: 20px;
            position: relative;
            z-index: 10;
        }

        /* Triforce Background */
        .triforce-bg {
            position: fixed;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            opacity: 0.05;
            z-index: 0;
            font-size: 300px;
            color: var(--gold);
        }

        /* Header */
        .header {
            text-align: center;
            padding: 30px;
            background: linear-gradient(180deg, var(--hyrule-dark) 0%, rgba(26,71,42,0.9) 100%);
            border: 4px solid var(--gold);
            border-radius: 8px;
            margin-bottom: 20px;
            position: relative;
        }

        .header::before, .header::after {
            content: '‚ñ≤';
            position: absolute;
            top: 10px;
            color: var(--gold);
            font-size: 24px;
        }
        .header::before { left: 20px; }
        .header::after { right: 20px; }

        .title {
            font-size: 1.5em;
            color: var(--gold);
            text-shadow: 3px 3px 0 var(--hyrule-dark), 0 0 20px var(--gold);
            margin-bottom: 10px;
        }

        .subtitle {
            font-size: 0.6em;
            color: var(--farore-green);
            text-shadow: 1px 1px 0 #000;
        }

        /* Stats Bar */
        .stats-bar {
            display: flex;
            justify-content: space-between;
            align-items: center;
            background: rgba(0,0,0,0.7);
            padding: 15px 20px;
            border: 3px solid var(--gold);
            border-radius: 8px;
            margin-bottom: 20px;
            flex-wrap: wrap;
            gap: 10px;
        }

        /* Hearts */
        .hearts-container {
            display: flex;
            gap: 8px;
        }

        .heart {
            width: 30px;
            height: 28px;
            position: relative;
        }

        .heart::before, .heart::after {
            content: '';
            position: absolute;
            width: 15px;
            height: 24px;
            background: var(--heart-red);
            border-radius: 15px 15px 0 0;
        }

        .heart::before {
            left: 0;
            transform: rotate(-45deg);
            transform-origin: bottom right;
        }

        .heart::after {
            right: 0;
            transform: rotate(45deg);
            transform-origin: bottom left;
        }

        .heart.empty::before, .heart.empty::after {
            background: #333;
            border: 2px solid #555;
        }

        .heart.lost {
            animation: heartLost 0.5s ease-out;
        }

        @keyframes heartLost {
            0% { transform: scale(1); }
            50% { transform: scale(1.3); filter: brightness(2); }
            100% { transform: scale(0.8); opacity: 0.5; }
        }

        /* Rupees */
        .rupee-counter {
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .rupee-icon {
            width: 20px;
            height: 30px;
            background: linear-gradient(135deg, #00ff00 0%, #008800 50%, #00ff00 100%);
            clip-path: polygon(50% 0%, 100% 25%, 100% 75%, 50% 100%, 0% 75%, 0% 25%);
            box-shadow: 0 0 10px #00ff00;
        }

        .rupee-value {
            font-size: 1.2em;
            color: var(--gold);
            text-shadow: 2px 2px 0 #000;
        }

        /* Dungeon/Category Info */
        .dungeon-info {
            text-align: center;
        }

        .dungeon-name {
            font-size: 0.6em;
            color: var(--nayru-blue);
            text-shadow: 1px 1px 0 #000;
        }

        .question-count {
            font-size: 0.5em;
            color: #aaa;
            margin-top: 5px;
        }

        /* Title Screen */
        .title-screen {
            text-align: center;
            padding: 40px 20px;
        }

        .game-logo {
            font-size: 2em;
            color: var(--gold);
            text-shadow: 4px 4px 0 var(--hyrule-dark), 0 0 30px var(--gold);
            margin-bottom: 30px;
            line-height: 1.5;
        }

        .triforce-display {
            font-size: 80px;
            color: var(--triforce-gold);
            text-shadow: 0 0 30px var(--gold);
            margin: 20px 0;
        }

        /* Category Selection */
        .category-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 15px;
            margin: 30px 0;
        }

        .category-card {
            background: linear-gradient(180deg, var(--hyrule-green) 0%, var(--hyrule-dark) 100%);
            border: 3px solid var(--gold);
            border-radius: 8px;
            padding: 20px;
            cursor: pointer;
            transition: all 0.3s;
            text-align: center;
        }

        .category-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(255,215,0,0.3);
            border-color: #fff;
        }

        .category-icon { font-size: 2em; margin-bottom: 10px; }
        .category-name { font-size: 0.7em; color: var(--gold); margin-bottom: 5px; }
        .category-subtitle { font-size: 0.5em; color: #aaa; }

        /* Difficulty Selection */
        .difficulty-select {
            display: flex;
            justify-content: center;
            gap: 20px;
            margin: 30px 0;
            flex-wrap: wrap;
        }

        .diff-btn {
            font-family: 'Press Start 2P', cursive;
            padding: 15px 25px;
            border: 3px solid;
            border-radius: 8px;
            cursor: pointer;
            font-size: 0.7em;
            transition: all 0.3s;
            background: transparent;
            color: #fff;
        }

        .diff-btn.intern { border-color: var(--farore-green); }
        .diff-btn.intern:hover { background: var(--farore-green); }
        .diff-btn.resident { border-color: var(--nayru-blue); }
        .diff-btn.resident:hover { background: var(--nayru-blue); }
        .diff-btn.fellow { border-color: var(--din-red); }
        .diff-btn.fellow:hover { background: var(--din-red); }

        /* Question Card */
        .question-card {
            background: linear-gradient(180deg, rgba(47,79,79,0.9) 0%, rgba(13,40,24,0.95) 100%);
            border: 4px solid var(--gold);
            border-radius: 8px;
            padding: 25px;
            margin-bottom: 20px;
        }

        .question-header {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-bottom: 15px;
            flex-wrap: wrap;
            gap: 10px;
        }

        .question-category {
            font-size: 0.5em;
            color: var(--nayru-blue);
            padding: 5px 10px;
            border: 2px solid var(--nayru-blue);
            border-radius: 4px;
        }

        .question-difficulty {
            font-size: 0.5em;
            padding: 5px 10px;
            border-radius: 4px;
        }

        .question-difficulty.intern { background: var(--farore-green); }
        .question-difficulty.resident { background: var(--nayru-blue); }
        .question-difficulty.fellow { background: var(--din-red); }

        .question-text {
            font-size: 0.8em;
            line-height: 2;
            color: var(--parchment);
            margin-bottom: 20px;
        }

        /* Answer Options */
        .options-container { display: flex; flex-direction: column; gap: 12px; }

        .option-btn {
            font-family: 'Press Start 2P', cursive;
            font-size: 0.6em;
            padding: 15px 20px;
            background: linear-gradient(180deg, var(--hyrule-green) 0%, var(--hyrule-dark) 100%);
            border: 3px solid var(--gold-dark);
            border-radius: 8px;
            color: #fff;
            cursor: pointer;
            text-align: left;
            transition: all 0.2s;
            line-height: 1.8;
        }

        .option-btn:hover:not(:disabled) {
            border-color: var(--gold);
            transform: translateX(10px);
            box-shadow: 0 0 15px rgba(255,215,0,0.3);
        }

        .option-btn.correct {
            background: linear-gradient(180deg, #228B22 0%, #006400 100%);
            border-color: #00ff00;
            animation: correctPulse 0.5s ease;
        }

        .option-btn.incorrect {
            background: linear-gradient(180deg, #8B0000 0%, #4a0000 100%);
            border-color: #ff0000;
            animation: incorrectShake 0.5s ease;
        }

        @keyframes correctPulse {
            0%, 100% { transform: scale(1); }
            50% { transform: scale(1.02); }
        }

        @keyframes incorrectShake {
            0%, 100% { transform: translateX(0); }
            25% { transform: translateX(-10px); }
            75% { transform: translateX(10px); }
        }

        /* Feedback Panel */
        .feedback-panel {
            background: rgba(0,0,0,0.9);
            border: 3px solid var(--gold);
            border-radius: 8px;
            padding: 20px;
            margin-top: 20px;
            display: none;
        }

        .feedback-panel.show { display: block; animation: fadeIn 0.3s ease; }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(-10px); }
            to { opacity: 1; transform: translateY(0); }
        }

        .feedback-header {
            font-size: 1em;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .feedback-header.correct { color: #00ff00; }
        .feedback-header.incorrect { color: #ff6666; }

        .explanation {
            font-size: 0.55em;
            line-height: 2;
            color: #ddd;
            margin-bottom: 15px;
            padding: 15px;
            background: rgba(255,255,255,0.05);
            border-radius: 4px;
        }

        .key-point {
            font-size: 0.5em;
            color: var(--gold);
            padding: 10px;
            border-left: 3px solid var(--gold);
            margin-bottom: 15px;
            line-height: 1.8;
        }

        .citation-box {
            font-size: 0.45em;
            color: #aaa;
            padding: 10px;
            background: rgba(0,0,0,0.5);
            border-radius: 4px;
            line-height: 1.8;
        }

        .citation-box a {
            color: var(--nayru-blue);
            text-decoration: none;
        }

        .citation-box a:hover { text-decoration: underline; }

        .next-btn {
            font-family: 'Press Start 2P', cursive;
            font-size: 0.7em;
            padding: 15px 30px;
            background: linear-gradient(180deg, var(--gold) 0%, var(--gold-dark) 100%);
            border: none;
            border-radius: 8px;
            color: #000;
            cursor: pointer;
            margin-top: 20px;
            transition: all 0.2s;
        }

        .next-btn:hover {
            transform: scale(1.05);
            box-shadow: 0 0 20px var(--gold);
        }

        /* Streak Bonus */
        .streak-bonus {
            position: fixed;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            font-size: 1.5em;
            color: var(--gold);
            text-shadow: 0 0 30px var(--gold);
            z-index: 100;
            animation: streakPop 1.5s ease-out forwards;
            pointer-events: none;
        }

        @keyframes streakPop {
            0% { opacity: 0; transform: translate(-50%, -50%) scale(0.5); }
            20% { opacity: 1; transform: translate(-50%, -50%) scale(1.2); }
            80% { opacity: 1; }
            100% { opacity: 0; transform: translate(-50%, -70%) scale(1); }
        }

        /* Game Over / Victory Screen */
        .end-screen {
            text-align: center;
            padding: 40px 20px;
        }

        .end-title {
            font-size: 1.8em;
            margin-bottom: 20px;
        }

        .end-title.victory { color: var(--gold); text-shadow: 0 0 30px var(--gold); }
        .end-title.defeat { color: var(--din-red); text-shadow: 0 0 30px var(--din-red); }

        .final-stats {
            background: rgba(0,0,0,0.7);
            border: 3px solid var(--gold);
            border-radius: 8px;
            padding: 30px;
            margin: 20px auto;
            max-width: 400px;
        }

        .stat-row {
            display: flex;
            justify-content: space-between;
            padding: 10px 0;
            border-bottom: 1px solid #333;
            font-size: 0.6em;
        }

        .stat-row:last-child { border-bottom: none; }
        .stat-label { color: #aaa; }
        .stat-value { color: var(--gold); }

        .play-again-btn {
            font-family: 'Press Start 2P', cursive;
            font-size: 0.8em;
            padding: 20px 40px;
            background: linear-gradient(180deg, var(--farore-green) 0%, #006400 100%);
            border: 3px solid var(--gold);
            border-radius: 8px;
            color: #fff;
            cursor: pointer;
            margin-top: 30px;
            transition: all 0.2s;
        }

        .play-again-btn:hover {
            transform: scale(1.05);
            box-shadow: 0 0 20px var(--farore-green);
        }

        .back-btn {
            font-family: 'Press Start 2P', cursive;
            font-size: 0.6em;
            padding: 10px 20px;
            background: transparent;
            border: 2px solid #666;
            border-radius: 4px;
            color: #aaa;
            cursor: pointer;
            margin-top: 15px;
        }

        .back-btn:hover { border-color: #fff; color: #fff; }

        /* Hidden */
        .hidden { display: none !important; }

        /* Responsive */
        @media (max-width: 768px) {
            .title { font-size: 1.2em; }
            .game-logo { font-size: 1.2em; }
            .stats-bar { flex-direction: column; text-align: center; }
            .category-grid { grid-template-columns: 1fr; }
            .question-text { font-size: 0.7em; }
            .option-btn { font-size: 0.55em; padding: 12px 15px; }
        }

        /* Link icon */
        .link-icon {
            width: 60px;
            height: 60px;
            margin: 0 auto 20px;
            position: relative;
        }

        .link-hat {
            width: 40px;
            height: 25px;
            background: var(--farore-green);
            border-radius: 5px 5px 0 0;
            position: absolute;
            top: 0;
            left: 10px;
        }

        .link-hat::after {
            content: '';
            position: absolute;
            right: -15px;
            top: 5px;
            width: 20px;
            height: 15px;
            background: var(--farore-green);
            border-radius: 0 10px 10px 0;
        }

        .link-face {
            width: 30px;
            height: 25px;
            background: #FFE4C4;
            border-radius: 5px;
            position: absolute;
            top: 20px;
            left: 15px;
        }

        .link-body {
            width: 35px;
            height: 20px;
            background: var(--farore-green);
            position: absolute;
            top: 40px;
            left: 12px;
            border-radius: 0 0 5px 5px;
        }
    </style>
</head>
<body>
    <div class="triforce-bg">‚ñ≤</div>

    <div class="game-container">
        <header class="header">
            <h1 class="title">BREATH OF THE WILLEBRAND</h1>
            <p class="subtitle">A Benign Hematology Quest</p>
        </header>

        <!-- Title Screen -->
        <div id="titleScreen" class="title-screen">
            <div class="link-icon">
                <div class="link-hat"></div>
                <div class="link-face"></div>
                <div class="link-body"></div>
            </div>
            <div class="triforce-display">‚ñ≤</div>
            <p style="font-size: 0.7em; color: var(--gold); margin-bottom: 30px;">Select Your Dungeon</p>

            <div class="category-grid">
                <div class="category-card" onclick="selectCategory('bleeding')">
                    <div class="category-icon">ü©∏</div>
                    <div class="category-name">The Willebrand Shrine</div>
                    <div class="category-subtitle">Bleeding Disorders</div>
                </div>
                <div class="category-card" onclick="selectCategory('platelet')">
                    <div class="category-icon">üî¥</div>
                    <div class="category-name">The Plateaulet Temple</div>
                    <div class="category-subtitle">Platelet Disorders</div>
                </div>
                <div class="category-card" onclick="selectCategory('anemia')">
                    <div class="category-icon">‚öîÔ∏è</div>
                    <div class="category-name">The Iron Fortress</div>
                    <div class="category-subtitle">Anemias</div>
                </div>
                <div class="category-card" onclick="selectCategory('coag')">
                    <div class="category-icon">üåä</div>
                    <div class="category-name">The Cascade Cavern</div>
                    <div class="category-subtitle">Coagulation & Thrombosis</div>
                </div>
                <div class="category-card" onclick="selectCategory('thrombophilia')">
                    <div class="category-icon">üëë</div>
                    <div class="category-name">The Clot Kingdom</div>
                    <div class="category-subtitle">Thrombophilia</div>
                </div>
                <div class="category-card" onclick="selectCategory('wbc')">
                    <div class="category-icon">üèõÔ∏è</div>
                    <div class="category-name">The Leuko-Labyrinth</div>
                    <div class="category-subtitle">Benign WBC Disorders</div>
                </div>
                <div class="category-card" onclick="selectCategory('lab')">
                    <div class="category-icon">üî¨</div>
                    <div class="category-name">Hyrule Hospital Lab</div>
                    <div class="category-subtitle">Clinical Laboratory</div>
                </div>
            </div>
        </div>

        <!-- Difficulty Selection -->
        <div id="difficultyScreen" class="title-screen hidden">
            <h2 style="color: var(--gold); margin-bottom: 20px;">Choose Your Challenge</h2>
            <p id="selectedCategory" style="font-size: 0.6em; color: var(--nayru-blue); margin-bottom: 30px;"></p>

            <div class="difficulty-select">
                <button class="diff-btn intern" onclick="startGame('intern')">
                    üå± Kokiri Forest<br><span style="font-size: 0.7em;">Intern Level</span>
                </button>
                <button class="diff-btn resident" onclick="startGame('resident')">
                    üè∞ Hyrule Field<br><span style="font-size: 0.7em;">Resident Level</span>
                </button>
                <button class="diff-btn fellow" onclick="startGame('fellow')">
                    üåã Death Mountain<br><span style="font-size: 0.7em;">Fellow Level</span>
                </button>
            </div>

            <button class="back-btn" onclick="showTitleScreen()">‚Üê Back to Dungeons</button>
        </div>

        <!-- Game Screen -->
        <div id="gameScreen" class="hidden">
            <div class="stats-bar">
                <div class="hearts-container" id="heartsContainer">
                    <div class="heart"></div>
                    <div class="heart"></div>
                    <div class="heart"></div>
                </div>
                <div class="dungeon-info">
                    <div class="dungeon-name" id="dungeonName">The Willebrand Shrine</div>
                    <div class="question-count" id="questionCount">Question 1 of 10</div>
                </div>
                <div class="rupee-counter">
                    <div class="rupee-icon"></div>
                    <span class="rupee-value" id="rupeeCount">0</span>
                </div>
            </div>

            <div class="question-card" id="questionCard">
                <div class="question-header">
                    <span class="question-category" id="qCategory">Bleeding Disorders</span>
                    <span class="question-difficulty" id="qDifficulty">Intern</span>
                </div>
                <div class="question-text" id="questionText"></div>
                <div class="options-container" id="optionsContainer"></div>
            </div>

            <div class="feedback-panel" id="feedbackPanel">
                <div class="feedback-header" id="feedbackHeader"></div>
                <div class="explanation" id="explanation"></div>
                <div class="key-point" id="keyPoint"></div>
                <div class="citation-box" id="citationBox"></div>
                <button class="next-btn" id="nextBtn" onclick="nextQuestion()">Continue Quest ‚Üí</button>
            </div>
        </div>

        <!-- End Screen -->
        <div id="endScreen" class="end-screen hidden">
            <h2 class="end-title" id="endTitle">Quest Complete!</h2>
            <div class="triforce-display" id="endTriforce">‚ñ≤</div>
            <div class="final-stats">
                <div class="stat-row">
                    <span class="stat-label">Rupees Collected</span>
                    <span class="stat-value" id="finalRupees">0</span>
                </div>
                <div class="stat-row">
                    <span class="stat-label">Questions Answered</span>
                    <span class="stat-value" id="finalAnswered">0</span>
                </div>
                <div class="stat-row">
                    <span class="stat-label">Correct Answers</span>
                    <span class="stat-value" id="finalCorrect">0</span>
                </div>
                <div class="stat-row">
                    <span class="stat-label">Accuracy</span>
                    <span class="stat-value" id="finalAccuracy">0%</span>
                </div>
                <div class="stat-row">
                    <span class="stat-label">Best Streak</span>
                    <span class="stat-value" id="finalStreak">0</span>
                </div>
                <div class="stat-row">
                    <span class="stat-label">High Score</span>
                    <span class="stat-value" id="highScore">0</span>
                </div>
            </div>
            <button class="play-again-btn" onclick="showTitleScreen()">New Quest</button>
        </div>
    </div>

    <script>
        // Game State
        let currentCategory = '';
        let currentDifficulty = '';
        let currentQuestionIndex = 0;
        let hearts = 3;
        let rupees = 0;
        let streak = 0;
        let bestStreak = 0;
        let questionsAnswered = 0;
        let correctAnswers = 0;
        let gameQuestions = [];

        // Category labels
        const categoryLabels = {
            bleeding: 'The Willebrand Shrine',
            platelet: 'The Plateaulet Temple',
            anemia: 'The Iron Fortress',
            coag: 'The Cascade Cavern',
            thrombophilia: 'The Clot Kingdom',
            wbc: 'The Leuko-Labyrinth',
            lab: 'Hyrule Hospital Lab'
        };

        // Rupee values by difficulty
        const rupeeValues = {
            intern: 5,
            resident: 20,
            fellow: 50
        };

        // Question Bank
        const questions = {
            bleeding: [
                {
                    difficulty: 'intern',
                    question: 'What is the most common inherited bleeding disorder?',
                    options: ['Hemophilia A', 'von Willebrand disease', 'Hemophilia B', 'Factor XI deficiency'],
                    correct: 1,
                    explanation: 'von Willebrand disease affects approximately 1% of the population and is the most common inherited bleeding disorder. It results from quantitative or qualitative defects in von Willebrand factor.',
                    keyPoint: 'vWD is the most common inherited bleeding disorder (~1% prevalence). Type 1 (quantitative deficiency) is most common subtype.',
                    citation: 'Leebeek FWG, Eikenboom JCJ. von Willebrand disease. N Engl J Med. 2016;375:2067-2080',
                    pmid: '27959741',
                    doi: '10.1056/NEJMra1601561'
                },
                {
                    difficulty: 'intern',
                    question: 'Which factor is deficient in Hemophilia A?',
                    options: ['Factor VIII', 'Factor IX', 'Factor XI', 'von Willebrand factor'],
                    correct: 0,
                    explanation: 'Hemophilia A is caused by deficiency of Factor VIII. It is the most common severe inherited bleeding disorder, with an incidence of approximately 1 in 5,000 male births.',
                    keyPoint: 'Hemophilia A = Factor VIII deficiency. Hemophilia B = Factor IX deficiency. Both are X-linked recessive.',
                    citation: 'Srivastava A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158',
                    pmid: '32744769',
                    doi: '10.1111/hae.14046'
                },
                {
                    difficulty: 'intern',
                    question: 'DDAVP (desmopressin) works by which mechanism?',
                    options: ['Directly replacing Factor VIII', 'Releasing vWF and Factor VIII from endothelial stores', 'Inhibiting fibrinolysis', 'Activating platelets'],
                    correct: 1,
                    explanation: 'DDAVP stimulates release of von Willebrand factor and Factor VIII from Weibel-Palade bodies in endothelial cells. It is effective in mild hemophilia A and Type 1 vWD.',
                    keyPoint: 'DDAVP releases vWF/FVIII from endothelial stores. Useful in mild hemophilia A and Type 1 vWD. Tachyphylaxis occurs with repeated dosing.',
                    citation: 'Castaman G, et al. How I treat von Willebrand disease. Blood. 2019;134(5):317-324',
                    pmid: '31151983',
                    doi: '10.1182/blood.2019000026'
                },
                {
                    difficulty: 'resident',
                    question: 'A patient with Type 2B vWD has thrombocytopenia. What is the mechanism?',
                    options: ['Bone marrow suppression', 'Increased vWF affinity for platelets causing clearance', 'Splenic sequestration', 'Antibody-mediated destruction'],
                    correct: 1,
                    explanation: 'Type 2B vWD is caused by gain-of-function mutations that increase vWF affinity for platelet GPIb. This leads to spontaneous binding and clearance of platelet-vWF complexes.',
                    keyPoint: 'Type 2B = gain-of-function, increased GPIb binding, causes thrombocytopenia. DDAVP is contraindicated as it worsens thrombocytopenia.',
                    citation: 'Federici AB. Current and emerging approaches for assessing von Willebrand disease in 2016. Int J Lab Hematol. 2016;38 Suppl 1:41-49',
                    pmid: '27161430',
                    doi: '10.1111/ijlh.12501'
                },
                {
                    difficulty: 'resident',
                    question: 'Which test distinguishes Type 2N vWD from mild Hemophilia A?',
                    options: ['vWF:Ag level', 'Factor VIII:C level', 'vWF:FVIII binding assay', 'Ristocetin cofactor activity'],
                    correct: 2,
                    explanation: 'Type 2N vWD has defective vWF binding to Factor VIII, leading to rapid FVIII clearance. The vWF:FVIII binding assay directly tests this interaction.',
                    keyPoint: 'Type 2N = defective vWF-FVIII binding. Low FVIII, normal vWF. Autosomal recessive. vWF:FVIII binding assay is diagnostic.',
                    citation: 'Goodeve AC. Diagnosing von Willebrand disease: genetic analysis. Hematology Am Soc Hematol Educ Program. 2016;2016(1):678-682',
                    pmid: '27913545',
                    doi: '10.1182/asheducation-2016.1.678'
                },
                {
                    difficulty: 'fellow',
                    question: 'A patient with acquired von Willebrand syndrome (AVWS) has aortic stenosis. What is the recommended treatment approach?',
                    options: ['High-dose IVIG', 'Valve replacement', 'vWF concentrate alone', 'Recombinant Factor VIII'],
                    correct: 1,
                    explanation: 'AVWS associated with aortic stenosis (Heyde syndrome) is caused by shear stress-induced loss of high molecular weight vWF multimers. Definitive treatment is valve replacement.',
                    keyPoint: 'Heyde syndrome = AS + AVWS + GI bleeding. High shear cleaves HMW vWF multimers via ADAMTS13. Valve replacement is curative.',
                    citation: 'Vincentelli A, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349(4):343-349',
                    pmid: '12878741',
                    doi: '10.1056/NEJMoa022831'
                },
                {
                    difficulty: 'intern',
                    question: 'What is the inheritance pattern of Hemophilia A?',
                    options: ['Autosomal dominant', 'Autosomal recessive', 'X-linked recessive', 'X-linked dominant'],
                    correct: 2,
                    explanation: 'Hemophilia A and B are X-linked recessive disorders. Males with the mutation are affected, while females are typically carriers.',
                    keyPoint: 'Hemophilia A & B are X-linked recessive. Factor VIII and IX genes are on X chromosome. ~30% are de novo mutations.',
                    citation: 'Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779',
                    pmid: '11396445',
                    doi: '10.1056/NEJM200106073442307'
                },
                {
                    difficulty: 'resident',
                    question: 'Which bleeding disorder is associated with delayed bleeding after initial hemostasis?',
                    options: ['Hemophilia A', 'Factor XIII deficiency', 'vWD Type 1', 'Bernard-Soulier syndrome'],
                    correct: 1,
                    explanation: 'Factor XIII cross-links fibrin to stabilize the clot. Deficiency causes delayed bleeding (12-36 hours) as the unstabilized clot breaks down.',
                    keyPoint: 'Factor XIII deficiency = normal PT/PTT but delayed bleeding, poor wound healing, umbilical stump bleeding, miscarriages.',
                    citation: 'Muszbek L, et al. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91(3):931-972',
                    pmid: '21742792',
                    doi: '10.1152/physrev.00016.2010'
                },
                {
                    difficulty: 'fellow',
                    question: 'Emicizumab works by which mechanism?',
                    options: ['Replacing Factor VIII', 'Bispecific antibody bridging FIXa and FX', 'Inhibiting TFPI', 'Activating prothrombin directly'],
                    correct: 1,
                    explanation: 'Emicizumab is a bispecific antibody that bridges activated Factor IX (FIXa) and Factor X, mimicking the cofactor function of Factor VIII.',
                    keyPoint: 'Emicizumab bridges FIXa and FX, mimics FVIII cofactor function. Used in Hemophilia A with or without inhibitors. Subcutaneous, long half-life.',
                    citation: 'Oldenburg J, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017;377(9):809-818',
                    pmid: '28691557',
                    doi: '10.1056/NEJMoa1703068'
                },
                {
                    difficulty: 'intern',
                    question: 'Aminocaproic acid and tranexamic acid work by inhibiting:',
                    options: ['Thrombin', 'Plasmin/plasminogen', 'Factor Xa', 'Platelet aggregation'],
                    correct: 1,
                    explanation: 'Aminocaproic acid and tranexamic acid are lysine analogs that inhibit plasminogen activation and plasmin, thereby preventing fibrinolysis.',
                    keyPoint: 'Antifibrinolytics block plasmin. Useful adjunct in mucosal bleeding (dental, menorrhagia, epistaxis). Avoid in upper urinary tract bleeding.',
                    citation: 'Tengborn L, et al. Tranexamic acid--an old drug still going strong and making a revival. Thromb Res. 2015;135(2):231-242',
                    pmid: '25559460',
                    doi: '10.1016/j.thromres.2014.11.012'
                }
            ],
            platelet: [
                {
                    difficulty: 'intern',
                    question: 'What is the most common cause of isolated thrombocytopenia in adults?',
                    options: ['TTP', 'HIT', 'ITP', 'DIC'],
                    correct: 2,
                    explanation: 'Immune thrombocytopenia (ITP) is the most common cause of isolated thrombocytopenia in otherwise healthy adults, caused by autoantibodies against platelet glycoproteins.',
                    keyPoint: 'ITP = isolated thrombocytopenia with normal blood smear. Diagnosis of exclusion. Antiplatelet antibodies target GPIIb/IIIa or GPIb/IX.',
                    citation: 'Neunert C, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866',
                    pmid: '31794604',
                    doi: '10.1182/bloodadvances.2019000966'
                },
                {
                    difficulty: 'intern',
                    question: 'First-line treatment for newly diagnosed ITP in adults is:',
                    options: ['Platelet transfusion', 'Splenectomy', 'Corticosteroids', 'Rituximab'],
                    correct: 2,
                    explanation: 'Corticosteroids (prednisone 1mg/kg or dexamethasone 40mg x 4 days) are first-line treatment for ITP, with initial response rates of 70-80%.',
                    keyPoint: 'First-line ITP treatment: Corticosteroids (prednisone or dexamethasone). IVIG if rapid response needed. Treatment threshold: <30K or symptomatic bleeding.',
                    citation: 'Neunert C, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866',
                    pmid: '31794604',
                    doi: '10.1182/bloodadvances.2019000966'
                },
                {
                    difficulty: 'resident',
                    question: 'A patient on heparin develops a 50% drop in platelets on day 7. The 4Ts score is 6. What is the next best step?',
                    options: ['Continue heparin and observe', 'Stop heparin and start warfarin', 'Stop heparin and start argatroban', 'Stop heparin only'],
                    correct: 2,
                    explanation: 'With intermediate-high probability HIT (4Ts ‚â•4), heparin must be stopped and a non-heparin anticoagulant (argatroban, bivalirudin, fondaparinux) started immediately due to high thrombosis risk.',
                    keyPoint: 'HIT management: Stop ALL heparin, start non-heparin anticoagulant. Do not start warfarin until platelets recover (risk of warfarin-induced venous limb gangrene).',
                    citation: 'Cuker A, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392',
                    pmid: '30482768',
                    doi: '10.1182/bloodadvances.2018024489'
                },
                {
                    difficulty: 'resident',
                    question: 'The pathognomonic finding in TTP that distinguishes it from other TMAs is:',
                    options: ['Schistocytes on smear', 'Elevated LDH', 'Severe ADAMTS13 deficiency (<10%)', 'Neurological symptoms'],
                    correct: 2,
                    explanation: 'Severe ADAMTS13 deficiency (<10% activity) is specific for TTP and distinguishes it from other thrombotic microangiopathies. It can be acquired (autoantibody) or congenital.',
                    keyPoint: 'TTP = ADAMTS13 <10%. Acquired (antibody) or congenital (Upshaw-Schulman). HUS typically has normal ADAMTS13. Check ADAMTS13 before plasma exchange.',
                    citation: 'Joly BS, et al. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836-2846',
                    pmid: '28416507',
                    doi: '10.1182/blood-2016-10-709857'
                },
                {
                    difficulty: 'fellow',
                    question: 'A patient with TTP relapses after initial response to plasma exchange. ADAMTS13 is <10% with detectable inhibitor. Best next therapy?',
                    options: ['Increase plasma exchange frequency', 'Add rituximab', 'Caplacizumab', 'Splenectomy'],
                    correct: 1,
                    explanation: 'Rituximab is recommended for relapsed or refractory acquired TTP to eliminate the autoantibody-producing B cells. It reduces relapse rates and time to remission.',
                    keyPoint: 'Refractory/relapsed TTP: Add rituximab to PEX. Caplacizumab (anti-vWF) is adjunctive for acute episodes. Consider rituximab maintenance for multiple relapses.',
                    citation: 'Scully M, et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019;380(4):335-346',
                    pmid: '30625070',
                    doi: '10.1056/NEJMoa1806311'
                },
                {
                    difficulty: 'intern',
                    question: 'Bernard-Soulier syndrome is caused by deficiency of:',
                    options: ['GPIIb/IIIa', 'GPIb/IX/V', 'Dense granules', 'Alpha granules'],
                    correct: 1,
                    explanation: 'Bernard-Soulier syndrome results from deficiency of the GPIb/IX/V complex, which is required for platelet adhesion to vWF. It causes giant platelets and thrombocytopenia.',
                    keyPoint: 'Bernard-Soulier = GPIb/IX/V deficiency (adhesion defect). Giant platelets, thrombocytopenia, absent ristocetin aggregation. Glanzmann = GPIIb/IIIa deficiency (aggregation defect).',
                    citation: 'Nurden AT, Nurden P. Inherited thrombocytopenias: history, advances and perspectives. Haematologica. 2020;105(8):2004-2019',
                    pmid: '32527952',
                    doi: '10.3324/haematol.2019.233197'
                },
                {
                    difficulty: 'resident',
                    question: 'A patient with Glanzmann thrombasthenia needs surgery. What is the recommended hemostatic agent?',
                    options: ['DDAVP', 'Platelet transfusion', 'Recombinant Factor VIIa', 'Cryoprecipitate'],
                    correct: 2,
                    explanation: 'Platelet transfusion is first-line, but patients often develop HLA antibodies and become refractory. Recombinant Factor VIIa (rFVIIa) is an effective alternative that bypasses the platelet defect.',
                    keyPoint: 'Glanzmann treatment: Platelet transfusion ¬± rFVIIa. Antifibrinolytics as adjunct. rFVIIa useful when platelet refractory. Avoid repeat transfusions to prevent alloimmunization.',
                    citation: 'Poon MC, et al. New insights into the treatment of Glanzmann thrombasthenia. Transfus Med Rev. 2016;30(2):92-99',
                    pmid: '26856150',
                    doi: '10.1016/j.tmrv.2016.01.001'
                },
                {
                    difficulty: 'fellow',
                    question: 'What antibody target is specific for HIT?',
                    options: ['Platelet factor 4 (PF4)', 'PF4-heparin complex', 'GPIIb/IIIa', 'Thrombopoietin receptor'],
                    correct: 1,
                    explanation: 'HIT antibodies target the neoepitope formed when PF4 binds to heparin. The PF4-heparin complex, not PF4 alone, is the immunogenic target.',
                    keyPoint: 'HIT antibodies target PF4-heparin complex (neoepitope). IgG antibodies activate platelets via FcŒ≥RIIa. SRA is gold standard test, PF4-ELISA is screening test.',
                    citation: 'Greinacher A. Heparin-Induced Thrombocytopenia. N Engl J Med. 2015;373(3):252-261',
                    pmid: '26176382',
                    doi: '10.1056/NEJMcp1411910'
                },
                {
                    difficulty: 'intern',
                    question: 'Which medication is a thrombopoietin receptor agonist used in ITP?',
                    options: ['Rituximab', 'Romiplostim', 'Prednisone', 'Azathioprine'],
                    correct: 1,
                    explanation: 'Romiplostim (and eltrombopag, avatrombopag) are TPO receptor agonists that stimulate platelet production. They are used for chronic ITP refractory to first-line therapy.',
                    keyPoint: 'TPO-RAs (romiplostim, eltrombopag, avatrombopag) increase platelet production. Used for chronic ITP after steroid failure. ~80% response rate.',
                    citation: 'Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10-23',
                    pmid: '23821332',
                    doi: '10.1007/s12185-013-1382-0'
                },
                {
                    difficulty: 'resident',
                    question: 'Drug-induced thrombocytopenia from quinine is mediated by:',
                    options: ['Direct marrow suppression', 'Drug-dependent antibodies', 'Immune complex deposition', 'Decreased TPO production'],
                    correct: 1,
                    explanation: 'Quinine-induced thrombocytopenia is caused by drug-dependent antibodies that only bind platelets in the presence of the drug, causing rapid severe thrombocytopenia.',
                    keyPoint: 'Drug-dependent antibodies cause acute severe thrombocytopenia. Common culprits: quinine, quinidine, sulfonamides, vancomycin. Resolves with drug discontinuation.',
                    citation: 'Arnold DM, et al. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost. 2013;11(1):169-176',
                    pmid: '23121994',
                    doi: '10.1111/jth.12052'
                }
            ],
            anemia: [
                {
                    difficulty: 'intern',
                    question: 'What is the most common cause of anemia worldwide?',
                    options: ['B12 deficiency', 'Iron deficiency', 'Thalassemia', 'Anemia of chronic disease'],
                    correct: 1,
                    explanation: 'Iron deficiency anemia is the most common nutritional deficiency and cause of anemia worldwide, affecting approximately 2 billion people.',
                    keyPoint: 'Iron deficiency is #1 cause of anemia globally. Causes: blood loss (GI, menstrual), malabsorption (celiac, gastrectomy), increased demand (pregnancy), poor intake.',
                    citation: 'Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832-1843',
                    pmid: '25946282',
                    doi: '10.1056/NEJMra1401038'
                },
                {
                    difficulty: 'intern',
                    question: 'Which finding on peripheral smear is characteristic of iron deficiency anemia?',
                    options: ['Target cells', 'Hypersegmented neutrophils', 'Pencil cells (elliptocytes)', 'Howell-Jolly bodies'],
                    correct: 2,
                    explanation: 'Iron deficiency anemia shows microcytic, hypochromic red cells with increased RDW. Pencil cells (elliptocytes) are characteristic.',
                    keyPoint: 'Iron deficiency smear: Microcytosis, hypochromia, pencil cells, increased RDW. Target cells more common in thalassemia. Hypersegmented neutrophils = B12/folate deficiency.',
                    citation: 'Lopez A, et al. Iron deficiency anaemia. Lancet. 2016;387(10021):907-916',
                    pmid: '26314490',
                    doi: '10.1016/S0140-6736(15)60865-0'
                },
                {
                    difficulty: 'resident',
                    question: 'A patient has microcytic anemia with ferritin 200 ng/mL and elevated CRP. Most likely diagnosis?',
                    options: ['Iron deficiency anemia', 'Anemia of chronic disease', 'Thalassemia trait', 'Sideroblastic anemia'],
                    correct: 1,
                    explanation: 'Ferritin is an acute phase reactant. In anemia of chronic disease with inflammation (elevated CRP), ferritin is often normal or elevated despite functional iron deficiency.',
                    keyPoint: 'ACD: Ferritin normal/high, TIBC low, hepcidin elevated (traps iron in stores). Iron deficiency: Ferritin low, TIBC high. Ferritin <30 = iron deficiency regardless of inflammation.',
                    citation: 'Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023',
                    pmid: '15758012',
                    doi: '10.1056/NEJMra041809'
                },
                {
                    difficulty: 'intern',
                    question: 'Pernicious anemia is caused by antibodies against:',
                    options: ['Red blood cells', 'Intrinsic factor', 'Transferrin receptor', 'Erythropoietin'],
                    correct: 1,
                    explanation: 'Pernicious anemia is an autoimmune condition with antibodies against intrinsic factor and/or parietal cells, leading to B12 malabsorption.',
                    keyPoint: 'Pernicious anemia = autoimmune destruction of parietal cells or anti-IF antibodies. Causes B12 deficiency. Associated with other autoimmune conditions (thyroid, vitiligo).',
                    citation: 'Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149-160',
                    pmid: '23301732',
                    doi: '10.1056/NEJMcp1113996'
                },
                {
                    difficulty: 'resident',
                    question: 'Which finding distinguishes warm autoimmune hemolytic anemia (AIHA) from cold agglutinin disease?',
                    options: ['Spherocytes on smear', 'Positive direct Coombs test', 'DAT positive for IgG only vs C3 only', 'Elevated LDH'],
                    correct: 2,
                    explanation: 'Warm AIHA is mediated by IgG antibodies (DAT positive for IgG ¬± C3), while cold agglutinin disease is mediated by IgM causing complement activation (DAT positive for C3 only).',
                    keyPoint: 'Warm AIHA: IgG antibodies, DAT positive IgG ¬± C3, treat with steroids/rituximab. Cold agglutinin: IgM, DAT positive C3 only, avoid cold, rituximab for treatment.',
                    citation: 'Hill QA, et al. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017;176(3):395-411',
                    pmid: '28005293',
                    doi: '10.1111/bjh.14478'
                },
                {
                    difficulty: 'fellow',
                    question: 'A patient with chronic hemolysis develops acute aplastic crisis. What is the most likely cause?',
                    options: ['Folate deficiency', 'Parvovirus B19 infection', 'Splenic sequestration', 'Iron overload'],
                    correct: 1,
                    explanation: 'Parvovirus B19 infects erythroid progenitors, causing transient red cell aplasia. In patients with chronic hemolysis and shortened RBC survival, this leads to severe anemia.',
                    keyPoint: 'Parvovirus B19 targets erythroid progenitors (P antigen receptor). Causes aplastic crisis in chronic hemolysis (sickle cell, HS). Reticulocyte count drops to zero.',
                    citation: 'Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586-597',
                    pmid: '14762186',
                    doi: '10.1056/NEJMra030840'
                },
                {
                    difficulty: 'intern',
                    question: 'G6PD deficiency causes hemolysis through:',
                    options: ['Membrane defect', 'Oxidative stress', 'Antibody-mediated destruction', 'Complement activation'],
                    correct: 1,
                    explanation: 'G6PD is needed to maintain glutathione in its reduced form, which protects against oxidative damage. Deficiency leads to hemolysis with oxidative stress (infections, drugs, fava beans).',
                    keyPoint: 'G6PD deficiency: X-linked, episodic hemolysis triggered by oxidative stress. Triggers: Infections, sulfa drugs, primaquine, fava beans. Smear shows bite cells, Heinz bodies.',
                    citation: 'Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64-74',
                    pmid: '18177777',
                    doi: '10.1016/S0140-6736(08)60073-2'
                },
                {
                    difficulty: 'resident',
                    question: 'What distinguishes beta thalassemia major from intermedia clinically?',
                    options: ['Age at presentation', 'Transfusion dependence', 'Hemoglobin electrophoresis pattern', 'Geographic distribution'],
                    correct: 1,
                    explanation: 'Beta thalassemia major presents in early childhood and requires regular transfusions for survival. Intermedia has milder phenotype with transfusion independence or occasional transfusion needs.',
                    keyPoint: 'Beta thal major: Transfusion dependent, presents at 6-12 months. Intermedia: Variable severity, may not need regular transfusions. Both show elevated HbF and HbA2.',
                    citation: 'Taher AT, et al. Beta-thalassemia. N Engl J Med. 2021;384(8):727-743',
                    pmid: '33626255',
                    doi: '10.1056/NEJMra2021838'
                },
                {
                    difficulty: 'fellow',
                    question: 'A patient with sickle cell disease develops stroke. What is the recommended long-term management?',
                    options: ['Hydroxyurea alone', 'Chronic transfusion therapy', 'Bone marrow transplant only', 'Aspirin prophylaxis'],
                    correct: 1,
                    explanation: 'Chronic transfusion to maintain HbS <30% is standard of care for secondary stroke prevention in sickle cell disease. This reduces stroke recurrence from 70% to 10%.',
                    keyPoint: 'Sickle cell stroke: Acute exchange transfusion, then chronic transfusions (goal HbS <30%). Reduces recurrence from 70% to 10%. Consider BMT in eligible patients.',
                    citation: 'DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127(7):829-838',
                    pmid: '26758917',
                    doi: '10.1182/blood-2015-09-618579'
                },
                {
                    difficulty: 'intern',
                    question: 'Hereditary spherocytosis is caused by defects in:',
                    options: ['Hemoglobin chain synthesis', 'RBC membrane proteins', 'RBC enzymes', 'Iron absorption'],
                    correct: 1,
                    explanation: 'Hereditary spherocytosis results from defects in RBC membrane proteins (spectrin, ankyrin, band 3, protein 4.2) that link the cytoskeleton to the lipid bilayer.',
                    keyPoint: 'HS: Membrane protein defects (spectrin, ankyrin most common). Spherocytes, elevated MCHC, positive osmotic fragility. Splenectomy is curative for severe cases.',
                    citation: 'Perrotta S, et al. Hereditary spherocytosis. Lancet. 2008;372(9647):1411-1426',
                    pmid: '18940465',
                    doi: '10.1016/S0140-6736(08)61588-3'
                }
            ],
            coag: [
                {
                    difficulty: 'intern',
                    question: 'An isolated prolonged aPTT with normal PT most likely indicates deficiency of:',
                    options: ['Factor VII', 'Factor X', 'Factor VIII', 'Fibrinogen'],
                    correct: 2,
                    explanation: 'Isolated prolonged aPTT suggests deficiency in the intrinsic pathway (Factors VIII, IX, XI, XII) or contact factors. Factor VIII deficiency (hemophilia A) is most common.',
                    keyPoint: 'Isolated prolonged aPTT: Intrinsic pathway (VIII, IX, XI, XII), lupus anticoagulant, heparin. Isolated prolonged PT: Factor VII. Both prolonged: Common pathway (X, V, II, fibrinogen).',
                    citation: 'Chee YL, Crawford JC. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. Br J Haematol. 2008;140(5):496-504',
                    pmid: '18275427',
                    doi: '10.1111/j.1365-2141.2007.06968.x'
                },
                {
                    difficulty: 'intern',
                    question: 'What is the INR target range for mechanical mitral valve on warfarin?',
                    options: ['1.5-2.0', '2.0-3.0', '2.5-3.5', '3.0-4.0'],
                    correct: 2,
                    explanation: 'Mechanical mitral valves require higher anticoagulation intensity (INR 2.5-3.5) due to higher thrombotic risk compared to mechanical aortic valves (INR 2.0-3.0).',
                    keyPoint: 'Mechanical valve INR targets: Mitral 2.5-3.5, Aortic 2.0-3.0. Bileaflet aortic with no risk factors may be 2.0-3.0. Add aspirin 81mg if additional risk factors.',
                    citation: 'Nishimura RA, et al. 2017 AHA/ACC Focused Update on Prosthetic Valves. Circulation. 2017;135(25):e1159-e1195',
                    pmid: '28298458',
                    doi: '10.1161/CIR.0000000000000503'
                },
                {
                    difficulty: 'resident',
                    question: 'A mixing study corrects an isolated prolonged aPTT. This suggests:',
                    options: ['Factor VIII inhibitor', 'Lupus anticoagulant', 'Factor deficiency', 'Heparin contamination'],
                    correct: 2,
                    explanation: 'A mixing study that corrects indicates factor deficiency (providing the missing factor corrects the test). Non-correction suggests an inhibitor (lupus anticoagulant or factor inhibitor).',
                    keyPoint: 'Mixing study: Correction = factor deficiency. No correction = inhibitor. Lupus anticoagulant is time-independent. Factor inhibitors (esp FVIII) may be time-dependent (incubate at 37¬∞C).',
                    citation: 'Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost. 2014;40(2):163-171',
                    pmid: '24497115',
                    doi: '10.1055/s-0033-1364185'
                },
                {
                    difficulty: 'resident',
                    question: 'Which finding is NOT part of the DIC diagnostic criteria?',
                    options: ['Prolonged PT', 'Thrombocytopenia', 'Elevated D-dimer', 'Elevated fibrinogen'],
                    correct: 3,
                    explanation: 'DIC causes consumption of clotting factors including fibrinogen. Fibrinogen is typically low in overt DIC. Elevated fibrinogen would argue against DIC.',
                    keyPoint: 'DIC: Low fibrinogen (<100), prolonged PT/aPTT, thrombocytopenia, elevated D-dimer, schistocytes. ISTH score ‚â•5 = overt DIC. Treat underlying cause.',
                    citation: 'Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(1):24-33',
                    pmid: '19222477',
                    doi: '10.1111/j.1365-2141.2009.07600.x'
                },
                {
                    difficulty: 'fellow',
                    question: 'A patient on warfarin with INR 9.0 has no bleeding. What is the recommended management?',
                    options: ['FFP transfusion', 'Vitamin K 10mg IV', 'Hold warfarin and give vitamin K 2.5-5mg orally', 'Hold warfarin only'],
                    correct: 2,
                    explanation: 'For INR >9 without significant bleeding, hold warfarin and give oral vitamin K (2.5-5mg). FFP or IV vitamin K reserved for serious bleeding or need for urgent procedure.',
                    keyPoint: 'INR >9 no bleeding: Hold warfarin + oral vitamin K 2.5-5mg. INR 4.5-9 no bleeding: Hold warfarin ¬± low-dose vitamin K. Serious bleeding: 4-factor PCC + IV vitamin K.',
                    citation: 'Holbrook A, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. Chest. 2012;141(2 Suppl):e152S-e184S',
                    pmid: '22315259',
                    doi: '10.1378/chest.11-2295'
                },
                {
                    difficulty: 'intern',
                    question: 'The reversal agent for dabigatran is:',
                    options: ['Protamine', 'Vitamin K', 'Idarucizumab', 'Andexanet alfa'],
                    correct: 2,
                    explanation: 'Idarucizumab is a humanized monoclonal antibody fragment that specifically binds dabigatran, rapidly reversing its anticoagulant effect.',
                    keyPoint: 'DOAC reversal: Dabigatran = idarucizumab. Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) = andexanet alfa or 4-factor PCC.',
                    citation: 'Pollack CV Jr, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017;377(5):431-441',
                    pmid: '28693366',
                    doi: '10.1056/NEJMoa1707278'
                },
                {
                    difficulty: 'resident',
                    question: 'Which DOAC requires dose adjustment for both renal and hepatic function?',
                    options: ['Dabigatran', 'Rivaroxaban', 'Apixaban', 'Edoxaban'],
                    correct: 2,
                    explanation: 'Apixaban is metabolized by both hepatic and renal routes and requires dose reduction based on a combination of age, weight, and creatinine (if 2 of 3 criteria met).',
                    keyPoint: 'Apixaban dose reduction: 2 of 3: Age ‚â•80, weight ‚â§60kg, Cr ‚â•1.5. Dabigatran: Primarily renal, contraindicated if CrCl <30. Rivaroxaban: Avoid if CrCl <15.',
                    citation: 'January CT, et al. 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation. Circulation. 2019;140(2):e125-e151',
                    pmid: '30686041',
                    doi: '10.1161/CIR.0000000000000665'
                },
                {
                    difficulty: 'fellow',
                    question: 'The mechanism of heparin-induced anticoagulation primarily involves:',
                    options: ['Direct thrombin inhibition', 'Potentiation of antithrombin activity', 'Vitamin K antagonism', 'Platelet inhibition'],
                    correct: 1,
                    explanation: 'Unfractionated heparin binds antithrombin and accelerates its inhibition of thrombin (IIa) and Factor Xa by 1000-fold. LMWH primarily inhibits Factor Xa.',
                    keyPoint: 'UFH: Potentiates antithrombin, inhibits IIa and Xa equally. LMWH: Anti-Xa > anti-IIa. Monitor UFH with aPTT or anti-Xa. LMWH generally does not require monitoring.',
                    citation: 'Garcia DA, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. Chest. 2012;141(2 Suppl):e24S-e43S',
                    pmid: '22315264',
                    doi: '10.1378/chest.11-2291'
                },
                {
                    difficulty: 'intern',
                    question: 'PT primarily assesses which coagulation pathway?',
                    options: ['Intrinsic pathway', 'Extrinsic pathway', 'Common pathway only', 'Fibrinolytic pathway'],
                    correct: 1,
                    explanation: 'PT (prothrombin time) assesses the extrinsic pathway (Factor VII) and common pathway (X, V, II, fibrinogen). It is the test used to monitor warfarin.',
                    keyPoint: 'PT: Extrinsic (VII) + common pathway. aPTT: Intrinsic (VIII, IX, XI, XII) + common pathway. Thrombin time: Fibrinogen function and heparin.',
                    citation: 'Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc. 2007;82(7):864-873',
                    pmid: '17605969',
                    doi: '10.4065/82.7.864'
                },
                {
                    difficulty: 'resident',
                    question: 'Acquired Factor VIII inhibitors are most commonly associated with:',
                    options: ['Young healthy males', 'Pregnancy/postpartum', 'Iron deficiency', 'Hyperthyroidism'],
                    correct: 1,
                    explanation: 'Acquired hemophilia A (autoantibody against Factor VIII) is most commonly associated with the postpartum period, malignancy, autoimmune disease, and elderly patients.',
                    keyPoint: 'Acquired hemophilia A: Postpartum, autoimmune, malignancy, drugs, elderly. Presents with soft tissue bleeding (different from congenital). Treat bleeds with bypassing agents, eradicate inhibitor with immunosuppression.',
                    citation: 'Kruse-Jarres R, et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017;92(7):695-705',
                    pmid: '28470674',
                    doi: '10.1002/ajh.24777'
                }
            ],
            thrombophilia: [
                {
                    difficulty: 'intern',
                    question: 'What is the most common inherited thrombophilia?',
                    options: ['Antithrombin deficiency', 'Protein C deficiency', 'Factor V Leiden', 'Prothrombin G20210A'],
                    correct: 2,
                    explanation: 'Factor V Leiden is the most common inherited thrombophilia, present in approximately 5% of Caucasians. It causes resistance to activated protein C.',
                    keyPoint: 'Factor V Leiden: Most common inherited thrombophilia (5% Caucasians). Causes APC resistance. Heterozygotes: 5-7x VTE risk. Homozygotes: 50-80x risk.',
                    citation: 'Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011;13(1):1-16',
                    pmid: '21116184',
                    doi: '10.1097/GIM.0b013e3181faa0f2'
                },
                {
                    difficulty: 'intern',
                    question: 'Antiphospholipid syndrome requires which laboratory finding?',
                    options: ['Positive ANA', 'Persistent positive antiphospholipid antibody confirmed at 12 weeks', 'Low complement levels', 'Positive anti-dsDNA'],
                    correct: 1,
                    explanation: 'APS diagnosis requires persistent positive antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, or anti-beta2 glycoprotein I) confirmed at least 12 weeks apart.',
                    keyPoint: 'APS criteria: Clinical (thrombosis or pregnancy morbidity) + Laboratory (LA, aCL, or anti-Œ≤2GPI positive on 2 occasions ‚â•12 weeks apart). Triple positive = highest risk.',
                    citation: 'Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306',
                    pmid: '16420554',
                    doi: '10.1111/j.1538-7836.2006.01753.x'
                },
                {
                    difficulty: 'resident',
                    question: 'When is thrombophilia testing most appropriately performed?',
                    options: ['During acute VTE', 'While on warfarin', 'After completing anticoagulation', 'While on DOAC therapy'],
                    correct: 2,
                    explanation: 'Thrombophilia testing is most accurate after completing anticoagulation. Acute thrombosis and anticoagulant therapy affect protein C, S, antithrombin, and lupus anticoagulant testing.',
                    keyPoint: 'Test after stopping anticoagulation (2-4 weeks for warfarin, 2 days for DOACs). Acute VTE lowers AT, protein C, S. Warfarin lowers protein C, S. Heparin lowers AT.',
                    citation: 'Baglin T, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149(2):209-220',
                    pmid: '20128793',
                    doi: '10.1111/j.1365-2141.2009.08022.x'
                },
                {
                    difficulty: 'resident',
                    question: 'A patient with unprovoked DVT at age 50 asks about thrombophilia testing. What do you advise?',
                    options: ['Test everyone with unprovoked DVT', 'Testing rarely changes management', 'Test only if family history positive', 'Test only females'],
                    correct: 1,
                    explanation: 'Thrombophilia testing rarely changes clinical management. Duration of anticoagulation after unprovoked VTE is based on bleeding risk vs recurrence risk, not thrombophilia status.',
                    keyPoint: 'Thrombophilia testing seldom changes management. Most unprovoked VTE gets indefinite anticoagulation anyway. Consider testing if it affects family screening or pregnancy planning.',
                    citation: 'Stevens SM, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline. Chest. 2021;160(6):e545-e608',
                    pmid: '34352278',
                    doi: '10.1016/j.chest.2021.07.055'
                },
                {
                    difficulty: 'fellow',
                    question: 'Homozygous protein C deficiency in neonates presents as:',
                    options: ['Asymptomatic', 'Mild bruising', 'Purpura fulminans', 'Hemarthrosis'],
                    correct: 2,
                    explanation: 'Homozygous protein C deficiency causes severe thrombosis presenting as purpura fulminans (skin necrosis with DIC) in neonates within hours to days of birth.',
                    keyPoint: 'Homozygous protein C or S deficiency: Purpura fulminans at birth, requires immediate protein C concentrate or FFP. Heterozygotes: VTE risk increased 7-10x.',
                    citation: 'Goldenberg NA, Manco-Johnson MJ. Protein C deficiency. Haemophilia. 2008;14(6):1214-1221',
                    pmid: '19141162',
                    doi: '10.1111/j.1365-2516.2008.01838.x'
                },
                {
                    difficulty: 'intern',
                    question: 'The prothrombin G20210A mutation causes thrombosis by:',
                    options: ['Creating APC resistance', 'Increasing prothrombin levels', 'Decreasing antithrombin', 'Causing hyperhomocysteinemia'],
                    correct: 1,
                    explanation: 'The prothrombin G20210A mutation in the 3\' untranslated region increases prothrombin mRNA stability, leading to elevated prothrombin levels and increased thrombin generation.',
                    keyPoint: 'Prothrombin G20210A: Increases prothrombin levels ~30%. 2-3% of Caucasians. VTE risk 2-3x heterozygotes. Test by PCR, not factor assay.',
                    citation: 'Poort SR, et al. A common genetic variation in the 3\'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698-3703',
                    pmid: '8916933',
                    doi: '10.1182/blood.V88.10.3698.bloodjournal88103698'
                },
                {
                    difficulty: 'resident',
                    question: 'Warfarin-induced skin necrosis is associated with deficiency of:',
                    options: ['Factor V Leiden', 'Protein C or S', 'Antithrombin', 'Factor VIII'],
                    correct: 1,
                    explanation: 'Protein C and S have short half-lives and drop rapidly with warfarin initiation, causing transient hypercoagulability and skin necrosis, especially in protein C/S deficient patients.',
                    keyPoint: 'Warfarin skin necrosis: Protein C (8hr half-life) drops before other factors. Risk highest in protein C/S deficiency. Prevent by bridging with heparin until INR therapeutic.',
                    citation: 'Chan YC, et al. Warfarin induced skin necrosis. Br J Surg. 2000;87(3):266-272',
                    pmid: '10718793',
                    doi: '10.1046/j.1365-2168.2000.01352.x'
                },
                {
                    difficulty: 'fellow',
                    question: 'In catastrophic antiphospholipid syndrome (CAPS), first-line treatment includes all EXCEPT:',
                    options: ['Anticoagulation', 'High-dose steroids', 'Plasma exchange', 'Rituximab'],
                    correct: 3,
                    explanation: 'CAPS treatment includes anticoagulation, steroids, and plasma exchange or IVIG. Rituximab is reserved for refractory cases but is not first-line therapy.',
                    keyPoint: 'CAPS treatment: Anticoagulation + steroids + plasma exchange or IVIG. Treat triggers (infection, surgery). Eculizumab for refractory cases. High mortality (30-50%).',
                    citation: 'Cervera R, Rodr√≠guez-Pint√≥ I. Catastrophic antiphospholipid syndrome: Task force report summary. Lupus. 2014;23(12):1283-1285',
                    pmid: '25228730',
                    doi: '10.1177/0961203314540764'
                },
                {
                    difficulty: 'intern',
                    question: 'What duration of anticoagulation is recommended for provoked DVT (e.g., post-surgery)?',
                    options: ['Lifelong', '6 months', '3 months', '1 month'],
                    correct: 2,
                    explanation: 'Provoked VTE (major transient risk factor like surgery) has low recurrence risk after the provoking factor resolves. Standard treatment is 3 months of anticoagulation.',
                    keyPoint: 'Provoked VTE (major surgery, trauma): 3 months. Unprovoked VTE: Consider indefinite if low bleeding risk. Cancer-associated: LMWH or DOAC as long as cancer active.',
                    citation: 'Kearon C, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline. Chest. 2016;149(2):315-352',
                    pmid: '26867832',
                    doi: '10.1016/j.chest.2015.11.026'
                },
                {
                    difficulty: 'resident',
                    question: 'Lupus anticoagulant is best screened for using:',
                    options: ['Anticardiolipin antibody ELISA', 'Dilute Russell viper venom time (dRVVT)', 'Anti-beta2 glycoprotein I ELISA', 'Standard aPTT only'],
                    correct: 1,
                    explanation: 'dRVVT is the most sensitive and specific screening test for lupus anticoagulant. It directly activates Factor X, bypassing the contact pathway.',
                    keyPoint: 'LA testing: Screen with dRVVT and sensitive aPTT. Confirm with mixing study (no correction) and confirmatory test (phospholipid neutralization). Do not test on anticoagulants.',
                    citation: 'Pengo V, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7(10):1737-1740',
                    pmid: '19624461',
                    doi: '10.1111/j.1538-7836.2009.03555.x'
                }
            ],
            wbc: [
                {
                    difficulty: 'intern',
                    question: 'What is the most common cause of lymphocytosis in adults?',
                    options: ['CLL', 'Viral infection', 'Pertussis', 'Lymphoma'],
                    correct: 1,
                    explanation: 'Reactive lymphocytosis due to viral infections (EBV, CMV, viral hepatitis, HIV) is far more common than malignant causes in adults.',
                    keyPoint: 'Reactive lymphocytosis: Most common cause is viral infection. CLL is most common cause of persistent lymphocytosis in elderly. Look at smear morphology.',
                    citation: 'Davids MS, Steensma DP. Making sense of mature lymphocytosis. Curr Hematol Malig Rep. 2014;9(1):9-18',
                    pmid: '24407376',
                    doi: '10.1007/s11899-014-0198-1'
                },
                {
                    difficulty: 'intern',
                    question: 'Classic peripheral smear finding in infectious mononucleosis is:',
                    options: ['Hypersegmented neutrophils', 'Atypical lymphocytes (reactive lymphocytes)', 'Blast cells', 'Schistocytes'],
                    correct: 1,
                    explanation: 'Infectious mononucleosis (EBV infection) characteristically shows atypical lymphocytes - large lymphocytes with abundant cytoplasm and irregular nuclei, representing activated T cells.',
                    keyPoint: 'Atypical lymphocytes = activated T cells responding to EBV-infected B cells. >10% atypical lymphocytes suggests EBV/CMV. Also seen in other viral infections and drug reactions.',
                    citation: 'Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician. 2004;70(7):1279-1287',
                    pmid: '15508538',
                    doi: null
                },
                {
                    difficulty: 'resident',
                    question: 'Severe chronic neutropenia is defined as ANC less than:',
                    options: ['1500/ŒºL', '1000/ŒºL', '500/ŒºL', '200/ŒºL'],
                    correct: 2,
                    explanation: 'Severe neutropenia is defined as ANC <500/ŒºL. This significantly increases infection risk. Moderate neutropenia is ANC 500-1000/ŒºL.',
                    keyPoint: 'Neutropenia severity: Mild 1000-1500, Moderate 500-1000, Severe <500. Infection risk increases substantially with ANC <500, especially <200.',
                    citation: 'Dale DC. How I manage neutropenia. Br J Haematol. 2017;179(1):92-105',
                    pmid: '28815576',
                    doi: '10.1111/bjh.14866'
                },
                {
                    difficulty: 'resident',
                    question: 'Which medication most commonly causes drug-induced neutropenia?',
                    options: ['Aspirin', 'Clozapine', 'Metformin', 'Omeprazole'],
                    correct: 1,
                    explanation: 'Clozapine carries a significant risk of agranulocytosis (1-2%), requiring mandatory monitoring. Other common causes include antithyroid drugs, sulfasalazine, and chemotherapy.',
                    keyPoint: 'Clozapine: 1-2% agranulocytosis risk, mandatory WBC monitoring. Other high-risk drugs: methimazole/PTU, sulfasalazine, trimethoprim-sulfamethoxazole.',
                    citation: 'Andr√®s E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008;15(1):15-21',
                    pmid: '18043241',
                    doi: '10.1097/MOH.0b013e3282f15fb9'
                },
                {
                    difficulty: 'fellow',
                    question: 'Cyclic neutropenia is caused by mutations in:',
                    options: ['G-CSF receptor', 'ELANE gene', 'HAX1 gene', 'GATA2 gene'],
                    correct: 1,
                    explanation: 'Cyclic neutropenia is caused by mutations in ELANE (neutrophil elastase gene), the same gene mutated in severe congenital neutropenia (Kostmann syndrome).',
                    keyPoint: 'Cyclic neutropenia: ELANE mutations, 21-day cycles, ANC nadir with infection risk. Treat with G-CSF. Severe congenital neutropenia: also ELANE, but constant severe neutropenia.',
                    citation: 'Horwitz MS, et al. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat Genet. 1999;23(4):433-436',
                    pmid: '10581030',
                    doi: '10.1038/70544'
                },
                {
                    difficulty: 'intern',
                    question: 'The most common cause of eosinophilia in the developed world is:',
                    options: ['Parasitic infection', 'Allergic disease', 'Drug reaction', 'Eosinophilic GI disease'],
                    correct: 1,
                    explanation: 'Allergic diseases (asthma, allergic rhinitis, eczema) are the most common cause of eosinophilia in developed countries. Parasitic infections predominate in endemic areas.',
                    keyPoint: 'Eosinophilia causes (mnemonic NAACP): Neoplasm, Allergy/Asthma, Adrenal insufficiency, Collagen vascular disease, Parasites. Mild (<1500) often allergic.',
                    citation: 'Rothenberg ME. Eosinophilia. N Engl J Med. 1998;338(22):1592-1600',
                    pmid: '9603798',
                    doi: '10.1056/NEJM199805283382206'
                },
                {
                    difficulty: 'resident',
                    question: 'Steroids cause neutrophilia by what mechanism?',
                    options: ['Increased bone marrow production', 'Demargination of neutrophils', 'Decreased neutrophil apoptosis', 'All of the above'],
                    correct: 3,
                    explanation: 'Corticosteroids cause neutrophilia through multiple mechanisms: demargination from vessel walls, release from bone marrow reserves, and decreased apoptosis.',
                    keyPoint: 'Steroid-induced neutrophilia: Demargination (rapid), marrow release (hours), decreased apoptosis (days). WBC can reach 20-30K. Lymphopenia also occurs.',
                    citation: 'Shoenfeld Y, et al. Glucocorticoid-induced granulocytosis: relationship to the degree of leukocytosis and duration of therapy. Am J Med. 1981;71(5):773-778',
                    pmid: '7304649',
                    doi: '10.1016/0002-9343(81)90363-6'
                },
                {
                    difficulty: 'fellow',
                    question: 'Large granular lymphocyte (LGL) leukemia is associated with:',
                    options: ['Hypergammaglobulinemia', 'Rheumatoid arthritis and neutropenia', 'Eosinophilia', 'Polycythemia'],
                    correct: 1,
                    explanation: 'T-LGL leukemia is associated with autoimmune conditions, especially rheumatoid arthritis (25-30% of cases) and pure red cell aplasia. It typically presents with neutropenia.',
                    keyPoint: 'T-LGL leukemia: Indolent, associated with RA and other autoimmune conditions. Neutropenia is hallmark. CD3+, CD8+, CD57+. Treat with immunosuppression if symptomatic.',
                    citation: 'Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood. 2011;117(10):2764-2774',
                    pmid: '21190991',
                    doi: '10.1182/blood-2010-07-296962'
                },
                {
                    difficulty: 'intern',
                    question: 'Monocytosis (>1000/ŒºL) persisting for >3 months should raise concern for:',
                    options: ['Viral infection', 'Chronic myelomonocytic leukemia', 'ITP', 'Hemolytic anemia'],
                    correct: 1,
                    explanation: 'Persistent monocytosis (>1000/ŒºL for >3 months) is a criterion for CMML. Other causes include chronic infection, autoimmune disease, and recovery from neutropenia.',
                    keyPoint: 'Persistent monocytosis: Consider CMML (especially if dysplasia, splenomegaly). Rule out reactive causes: chronic infection (TB, endocarditis), autoimmune, malignancy.',
                    citation: 'Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(1):97-115',
                    pmid: '31736122',
                    doi: '10.1002/ajh.25684'
                },
                {
                    difficulty: 'resident',
                    question: 'Benign ethnic neutropenia is most commonly seen in individuals of which ancestry?',
                    options: ['Northern European', 'Asian', 'African/Middle Eastern', 'Native American'],
                    correct: 2,
                    explanation: 'Benign ethnic neutropenia (BEN) is common in individuals of African, Middle Eastern, and some European (e.g., Yemeni Jewish) descent, with prevalence of 25-50% in some populations.',
                    keyPoint: 'Benign ethnic neutropenia: Duffy-null phenotype (DARC gene). No increased infection risk. ANC 1000-1500 is normal for these populations. No treatment needed.',
                    citation: 'Hsieh MM, et al. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007;146(7):486-492',
                    pmid: '17404350',
                    doi: '10.7326/0003-4819-146-7-200704030-00004'
                }
            ],
            lab: [
                {
                    difficulty: 'intern',
                    question: 'An elevated reticulocyte count indicates:',
                    options: ['Bone marrow suppression', 'Increased RBC production', 'Hemoglobin variant', 'Iron deficiency'],
                    correct: 1,
                    explanation: 'Reticulocytes are immature RBCs. Elevated reticulocyte count indicates increased RBC production, typically seen in hemolysis or blood loss with adequate marrow response.',
                    keyPoint: 'High reticulocytes: Hemolysis, acute blood loss, treatment response. Low reticulocytes with anemia: Marrow failure, nutritional deficiency, anemia of chronic disease.',
                    citation: 'Piva E, et al. Automated reticulocyte counting: state of the art and clinical applications in the evaluation of erythropoiesis. Clin Chem Lab Med. 2010;48(10):1369-1380',
                    pmid: '20491596',
                    doi: '10.1515/CCLM.2010.292'
                },
                {
                    difficulty: 'intern',
                    question: 'Target cells on peripheral smear are seen in all EXCEPT:',
                    options: ['Thalassemia', 'Liver disease', 'Hereditary spherocytosis', 'Hemoglobin C disease'],
                    correct: 2,
                    explanation: 'Target cells form when there is excess membrane relative to cell volume. Hereditary spherocytosis has the opposite - decreased membrane surface area, forming spherocytes.',
                    keyPoint: 'Target cells: Thalassemia, liver disease, HbC, post-splenectomy, iron deficiency. Spherocytes: HS, AIHA, burns, Clostridium sepsis.',
                    citation: 'Bain BJ. Diagnosis from the blood smear. N Engl J Med. 2005;353(5):498-507',
                    pmid: '16079373',
                    doi: '10.1056/NEJMra043442'
                },
                {
                    difficulty: 'resident',
                    question: 'A patient has low hemoglobin with high MCV. The reticulocyte count is low. Most likely cause?',
                    options: ['Acute blood loss', 'Hemolysis', 'B12 or folate deficiency', 'Thalassemia'],
                    correct: 2,
                    explanation: 'Macrocytic anemia with low reticulocyte count suggests impaired RBC production. B12 or folate deficiency causes megaloblastic anemia with ineffective erythropoiesis.',
                    keyPoint: 'Macrocytic anemia + low retics: B12/folate deficiency, MDS, hypothyroidism, liver disease, drugs (hydroxyurea, MTX). High retics: Hemolysis with reticulocytosis (retics are large).',
                    citation: 'Green R, Datta Mitra A. Megaloblastic Anemias: Nutritional and Other Causes. Med Clin North Am. 2017;101(2):297-317',
                    pmid: '28189172',
                    doi: '10.1016/j.mcna.2016.09.013'
                },
                {
                    difficulty: 'resident',
                    question: 'Which iron study pattern indicates iron deficiency anemia?',
                    options: ['Low ferritin, low TIBC, low serum iron', 'Low ferritin, high TIBC, low serum iron', 'High ferritin, low TIBC, low serum iron', 'Normal ferritin, normal TIBC, low serum iron'],
                    correct: 1,
                    explanation: 'Iron deficiency shows low serum iron, low ferritin (storage depleted), and high TIBC (body trying to capture more iron). Transferrin saturation is low.',
                    keyPoint: 'Iron deficiency: ‚ÜìIron, ‚ÜìFerritin, ‚ÜëTIBC, ‚ÜìSat%. ACD: ‚ÜìIron, ‚ÜëFerritin, ‚ÜìTIBC, ‚ÜìSat%. Ferritin <30 = iron deficient even with inflammation.',
                    citation: 'Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832-1843',
                    pmid: '25946282',
                    doi: '10.1056/NEJMra1401038'
                },
                {
                    difficulty: 'fellow',
                    question: 'The direct antiglobulin test (DAT) detects:',
                    options: ['Antibodies in patient serum', 'Antibodies/complement bound to RBC surface', 'Free hemoglobin in plasma', 'Haptoglobin levels'],
                    correct: 1,
                    explanation: 'The DAT (direct Coombs test) detects IgG and/or complement (C3) bound to the patient\'s RBCs. It is positive in autoimmune hemolytic anemia and some drug-induced hemolysis.',
                    keyPoint: 'DAT: Detects antibodies/complement ON RBCs. Positive in AIHA, HDN, drug-induced hemolysis. IAT (indirect Coombs): Detects antibodies in serum (used for crossmatch, antibody screen).',
                    citation: 'Parker V, Tormey CA. The Direct Antiglobulin Test: Indications, Interpretation, and Pitfalls. Arch Pathol Lab Med. 2017;141(2):305-310',
                    pmid: '28134590',
                    doi: '10.5858/arpa.2015-0444-RS'
                },
                {
                    difficulty: 'intern',
                    question: 'Schistocytes on peripheral smear suggest:',
                    options: ['Iron deficiency', 'Microangiopathic hemolytic anemia', 'Megaloblastic anemia', 'Spherocytosis'],
                    correct: 1,
                    explanation: 'Schistocytes (helmet cells, fragmented RBCs) indicate mechanical RBC destruction, seen in microangiopathic hemolytic anemia (TTP, HUS, DIC) and mechanical heart valves.',
                    keyPoint: 'Schistocytes = MAHA: TTP, HUS, DIC, malignant HTN, HELLP, mechanical valves, aortic stenosis, marching hemoglobinuria. >1% is significant.',
                    citation: 'Lesesve JF, et al. Schistocytes in disseminated intravascular coagulation. Int J Lab Hematol. 2014;36(4):439-443',
                    pmid: '24373126',
                    doi: '10.1111/ijlh.12168'
                },
                {
                    difficulty: 'resident',
                    question: 'Hemoglobin electrophoresis in beta thalassemia trait typically shows:',
                    options: ['Elevated HbA2 and HbF', 'Elevated HbS', 'Normal pattern', 'Elevated HbH'],
                    correct: 0,
                    explanation: 'Beta thalassemia trait shows elevated HbA2 (>3.5%) and often mildly elevated HbF. This helps distinguish it from iron deficiency, which has normal electrophoresis.',
                    keyPoint: 'Beta thal trait: ‚ÜëHbA2 (>3.5%), ¬±‚ÜëHbF, microcytosis, normal/high RBC count. Iron deficiency: Normal HbA2, ‚ÜìRBC count. Check iron studies before electrophoresis.',
                    citation: 'Cao A, Galanello R. Beta-thalassemia. Genet Med. 2010;12(2):61-76',
                    pmid: '20098328',
                    doi: '10.1097/GIM.0b013e3181cd68ed'
                },
                {
                    difficulty: 'fellow',
                    question: 'Flow cytometry finding specific for paroxysmal nocturnal hemoglobinuria (PNH) is:',
                    options: ['Absence of CD55 and CD59', 'Presence of CD5', 'Absence of CD34', 'Presence of CD38'],
                    correct: 0,
                    explanation: 'PNH RBCs and WBCs lack GPI-anchored proteins including CD55 and CD59 (complement regulatory proteins). Flow cytometry detecting absence of these markers is diagnostic.',
                    keyPoint: 'PNH flow cytometry: Absence of GPI-anchored proteins (CD55, CD59) on RBCs and granulocytes. FLAER assay is most sensitive for WBCs. Clone size correlates with hemolysis.',
                    citation: 'Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804-2811',
                    pmid: '25237200',
                    doi: '10.1182/blood-2014-02-522128'
                },
                {
                    difficulty: 'intern',
                    question: 'Elevated LDH with low haptoglobin suggests:',
                    options: ['Liver disease', 'Hemolysis', 'Myocardial infarction', 'Nutritional deficiency'],
                    correct: 1,
                    explanation: 'Hemolysis releases LDH from RBCs, elevating serum LDH. Free hemoglobin binds haptoglobin, which is cleared, resulting in low or undetectable haptoglobin.',
                    keyPoint: 'Hemolysis markers: ‚ÜëLDH, ‚ÜìHaptoglobin, ‚ÜëIndirect bilirubin, ‚ÜëReticulocytes. Intravascular hemolysis also shows hemoglobinuria, hemosiderinuria.',
                    citation: 'Marchand A, et al. The predictive value of serum haptoglobin in hemolytic disease. JAMA. 1980;243(19):1909-1911',
                    pmid: '7365974',
                    doi: '10.1001/jama.1980.03300450023014'
                },
                {
                    difficulty: 'resident',
                    question: 'Thrombin time is prolonged by all EXCEPT:',
                    options: ['Heparin', 'Fibrinogen deficiency', 'Warfarin', 'Thrombin inhibitors'],
                    correct: 2,
                    explanation: 'Thrombin time measures conversion of fibrinogen to fibrin by thrombin. Warfarin affects vitamin K-dependent factors (II, VII, IX, X) but not this final step.',
                    keyPoint: 'Thrombin time prolonged: Heparin, hypofibrinogenemia, dysfibrinogenemia, thrombin inhibitors (dabigatran, argatroban), high FDP. Not prolonged by warfarin.',
                    citation: 'Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc. 2007;82(7):864-873',
                    pmid: '17605969',
                    doi: '10.4065/82.7.864'
                }
            ]
        };

        // Sound effects
        function playSound(type) {
            try {
                const ctx = new (window.AudioContext || window.webkitAudioContext)();
                const osc = ctx.createOscillator();
                const gain = ctx.createGain();
                osc.connect(gain);
                gain.connect(ctx.destination);

                if (type === 'correct') {
                    osc.frequency.setValueAtTime(523, ctx.currentTime);
                    osc.frequency.setValueAtTime(659, ctx.currentTime + 0.1);
                    osc.frequency.setValueAtTime(784, ctx.currentTime + 0.2);
                    gain.gain.setValueAtTime(0.3, ctx.currentTime);
                    gain.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.4);
                    osc.start(ctx.currentTime);
                    osc.stop(ctx.currentTime + 0.4);
                } else if (type === 'wrong') {
                    osc.frequency.setValueAtTime(200, ctx.currentTime);
                    osc.frequency.setValueAtTime(150, ctx.currentTime + 0.15);
                    gain.gain.setValueAtTime(0.3, ctx.currentTime);
                    gain.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.3);
                    osc.start(ctx.currentTime);
                    osc.stop(ctx.currentTime + 0.3);
                } else if (type === 'streak') {
                    [523, 659, 784, 1047].forEach((freq, i) => {
                        const o = ctx.createOscillator();
                        const g = ctx.createGain();
                        o.connect(g);
                        g.connect(ctx.destination);
                        o.frequency.value = freq;
                        g.gain.setValueAtTime(0.2, ctx.currentTime + i * 0.1);
                        g.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + i * 0.1 + 0.2);
                        o.start(ctx.currentTime + i * 0.1);
                        o.stop(ctx.currentTime + i * 0.1 + 0.2);
                    });
                }
            } catch(e) {}
        }

        // Select category
        function selectCategory(category) {
            currentCategory = category;
            document.getElementById('selectedCategory').textContent = categoryLabels[category];
            document.getElementById('titleScreen').classList.add('hidden');
            document.getElementById('difficultyScreen').classList.remove('hidden');
        }

        // Start game
        function startGame(difficulty) {
            currentDifficulty = difficulty;

            // Filter questions by category and difficulty
            let categoryQuestions = questions[currentCategory].filter(q => q.difficulty === difficulty);

            // Shuffle and take 10 questions
            gameQuestions = categoryQuestions.sort(() => Math.random() - 0.5).slice(0, 10);

            // If not enough questions of exact difficulty, add from other difficulties
            if (gameQuestions.length < 10) {
                let otherQuestions = questions[currentCategory]
                    .filter(q => q.difficulty !== difficulty)
                    .sort(() => Math.random() - 0.5);
                gameQuestions = [...gameQuestions, ...otherQuestions].slice(0, 10);
            }

            // Reset game state
            currentQuestionIndex = 0;
            hearts = 3;
            rupees = 0;
            streak = 0;
            bestStreak = 0;
            questionsAnswered = 0;
            correctAnswers = 0;

            // Update UI
            document.getElementById('dungeonName').textContent = categoryLabels[currentCategory];
            updateHearts();
            updateRupees();

            // Show game screen
            document.getElementById('difficultyScreen').classList.add('hidden');
            document.getElementById('gameScreen').classList.remove('hidden');

            showQuestion();
        }

        // Show question
        function showQuestion() {
            if (currentQuestionIndex >= gameQuestions.length || hearts <= 0) {
                endGame();
                return;
            }

            const q = gameQuestions[currentQuestionIndex];

            document.getElementById('questionCount').textContent = `Question ${currentQuestionIndex + 1} of ${gameQuestions.length}`;
            document.getElementById('qCategory').textContent = categoryLabels[currentCategory].replace('The ', '').replace(' Shrine', '').replace(' Temple', '').replace(' Fortress', '').replace(' Cavern', '').replace(' Kingdom', '').replace(' Labyrinth', '').replace(' Hospital Lab', '');

            const diffBadge = document.getElementById('qDifficulty');
            diffBadge.textContent = q.difficulty.charAt(0).toUpperCase() + q.difficulty.slice(1);
            diffBadge.className = 'question-difficulty ' + q.difficulty;

            document.getElementById('questionText').textContent = q.question;

            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';

            q.options.forEach((opt, i) => {
                const btn = document.createElement('button');
                btn.className = 'option-btn';
                btn.textContent = `${String.fromCharCode(65 + i)}. ${opt}`;
                btn.onclick = () => selectAnswer(i);
                optionsContainer.appendChild(btn);
            });

            document.getElementById('feedbackPanel').classList.remove('show');
        }

        // Select answer
        function selectAnswer(index) {
            const q = gameQuestions[currentQuestionIndex];
            const buttons = document.querySelectorAll('.option-btn');

            buttons.forEach(btn => btn.disabled = true);

            questionsAnswered++;

            if (index === q.correct) {
                // Correct answer
                buttons[index].classList.add('correct');
                playSound('correct');

                correctAnswers++;
                streak++;
                if (streak > bestStreak) bestStreak = streak;

                // Add rupees
                rupees += rupeeValues[q.difficulty];
                updateRupees();

                // Check for streak bonus
                if (streak % 5 === 0) {
                    playSound('streak');
                    rupees += 100;
                    updateRupees();
                    showStreakBonus();
                }

                showFeedback(true, q);
            } else {
                // Wrong answer
                buttons[index].classList.add('incorrect');
                buttons[q.correct].classList.add('correct');
                playSound('wrong');

                streak = 0;
                hearts--;
                updateHearts();

                showFeedback(false, q);
            }
        }

        // Show feedback
        function showFeedback(correct, q) {
            const panel = document.getElementById('feedbackPanel');
            const header = document.getElementById('feedbackHeader');

            header.className = 'feedback-header ' + (correct ? 'correct' : 'incorrect');
            header.innerHTML = correct ? '‚úì CORRECT! +' + rupeeValues[q.difficulty] + ' Rupees' : '‚úó INCORRECT - Lost a heart';

            document.getElementById('explanation').textContent = q.explanation;
            document.getElementById('keyPoint').innerHTML = '‚öîÔ∏è Key Point: ' + q.keyPoint;

            let citationHTML = `<strong>Citation:</strong> ${q.citation}<br>`;
            if (q.pmid) {
                citationHTML += `<a href="https://pubmed.ncbi.nlm.nih.gov/${q.pmid}/" target="_blank">PMID: ${q.pmid}</a>`;
            }
            if (q.doi) {
                citationHTML += ` | <a href="https://doi.org/${q.doi}" target="_blank">DOI</a>`;
            }
            document.getElementById('citationBox').innerHTML = citationHTML;

            panel.classList.add('show');

            // Change button text if game will end
            const nextBtn = document.getElementById('nextBtn');
            if (currentQuestionIndex >= gameQuestions.length - 1 || hearts <= 0) {
                nextBtn.textContent = 'See Results ‚Üí';
            } else {
                nextBtn.textContent = 'Continue Quest ‚Üí';
            }
        }

        // Next question
        function nextQuestion() {
            currentQuestionIndex++;
            showQuestion();
        }

        // Update hearts display
        function updateHearts() {
            const container = document.getElementById('heartsContainer');
            container.innerHTML = '';
            for (let i = 0; i < 3; i++) {
                const heart = document.createElement('div');
                heart.className = 'heart' + (i >= hearts ? ' empty' : '');
                if (i === hearts) heart.classList.add('lost');
                container.appendChild(heart);
            }
        }

        // Update rupees display
        function updateRupees() {
            document.getElementById('rupeeCount').textContent = rupees;
        }

        // Show streak bonus
        function showStreakBonus() {
            const bonus = document.createElement('div');
            bonus.className = 'streak-bonus';
            bonus.innerHTML = '‚öîÔ∏è MASTER SWORD BONUS! +100 Rupees';
            document.body.appendChild(bonus);
            setTimeout(() => bonus.remove(), 1500);
        }

        // End game
        function endGame() {
            document.getElementById('gameScreen').classList.add('hidden');
            document.getElementById('endScreen').classList.remove('hidden');

            const endTitle = document.getElementById('endTitle');
            const endTriforce = document.getElementById('endTriforce');

            if (hearts > 0) {
                endTitle.textContent = 'Quest Complete!';
                endTitle.className = 'end-title victory';
                endTriforce.style.color = 'var(--triforce-gold)';
            } else {
                endTitle.textContent = 'Game Over';
                endTitle.className = 'end-title defeat';
                endTriforce.style.color = 'var(--din-red)';
            }

            document.getElementById('finalRupees').textContent = rupees;
            document.getElementById('finalAnswered').textContent = questionsAnswered;
            document.getElementById('finalCorrect').textContent = correctAnswers;
            document.getElementById('finalAccuracy').textContent = questionsAnswered > 0 ? Math.round((correctAnswers / questionsAnswered) * 100) + '%' : '0%';
            document.getElementById('finalStreak').textContent = bestStreak;

            // High score
            const highScoreKey = 'breathOfWillebrandHighScore';
            const currentHigh = parseInt(localStorage.getItem(highScoreKey) || '0');
            if (rupees > currentHigh) {
                localStorage.setItem(highScoreKey, rupees);
            }
            document.getElementById('highScore').textContent = Math.max(rupees, currentHigh);
        }

        // Show title screen
        function showTitleScreen() {
            document.getElementById('titleScreen').classList.remove('hidden');
            document.getElementById('difficultyScreen').classList.add('hidden');
            document.getElementById('gameScreen').classList.add('hidden');
            document.getElementById('endScreen').classList.add('hidden');
        }
    </script>
</body>
</html>
